Skip to main content
Top
Published in: Diabetologia 5/2011

01-05-2011 | Article

Insulin resistance influences the association of adiponectin levels with diabetes incidence in two population-based cohorts: the Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 study and the Framingham Offspring Study

Authors: M.-F. Hivert, L. M. Sullivan, P. Shrader, C. S. Fox, D. M. Nathan, R. B. D’Agostino Sr, P. W. F. Wilson, B. Kowall, C. Herder, C. Meisinger, B. Thorand, W. Rathmann, J. B. Meigs

Published in: Diabetologia | Issue 5/2011

Login to get access

Abstract

Aims/hypothesis

Lower adiponectin levels are associated with higher risk of incident type 2 diabetes. Most analyses have been adjusted for confounding factors, but few have taken into account insulin resistance per se. We tested the hypothesis that the association of adiponectin levels with incident type 2 diabetes differs between insulin-resistant and insulin-sensitive individuals.

Methods

We studied two prospective cohorts: the Framingham Offspring Study (n = 2,023) and the Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 study (n = 887) cohorts. Insulin resistance was estimated by HOMA-insulin resistance (HOMA-IR). We used logistic regression analysis to test the association between adiponectin and incident type 2 diabetes overall and in insulin-resistant vs insulin-sensitive individuals (defined by ≥ vs <75th percentile of HOMA-IR).

Results

At baseline, Framingham’s participants were 60 ± 9 years old and 56% were women; KORA’s participants were 63 ± 5 years old and 49% were women. Type 2 diabetes incidence was 5.4% over 6.5 years (n = 109) in Framingham and 10.5% over 8 years (n = 93) in KORA. Lower adiponectin levels were associated with type 2 diabetes incidence in both cohorts. In insulin-resistant individuals, lower adiponectin levels were associated with higher risk of type 2 diabetes incidence (OR 1.60 [95% CI 1.10–2.31] per SD decrease in Framingham, p = 0.01; and OR 2.34 [95% CI 1.16–4.73] in KORA, p = 0.02); while this was not observed in insulin-sensitive individuals (OR 1.10 [95% CI 0.73–1.67] in Framingham, p = 0.64; and OR 1.34 [95%CI: 0.88–2.03] in KORA, p = 0.18).

Conclusions/interpretation

We conclude that lower adiponectin levels are associated with higher risk of type 2 diabetes in insulin-resistant but not in insulin-sensitive individuals. This suggests that some level of insulin resistance is needed to see deleterious effects of low adiponectin.
Appendix
Available only for authorised users
Literature
1.
go back to reference Li S, Shin JJ, Ding EL, van Dam RM (2009) Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302:179–188PubMedCrossRef Li S, Shin JJ, Ding EL, van Dam RM (2009) Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302:179–188PubMedCrossRef
2.
go back to reference Hivert MF, Manning AK, McAteer JB et al (2008) Common variants in the adiponectin gene (ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes, and diabetes-related quantitative traits: the Framingham Offspring Study. Diabetes 57:3353–3359PubMedCrossRef Hivert MF, Manning AK, McAteer JB et al (2008) Common variants in the adiponectin gene (ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes, and diabetes-related quantitative traits: the Framingham Offspring Study. Diabetes 57:3353–3359PubMedCrossRef
3.
go back to reference Kannel WB, Gordon T, Castelli WP (1979) Obesity, lipids, and glucose intolerance. The Framingham Study. Am J Clin Nutr 32:1238–1245PubMed Kannel WB, Gordon T, Castelli WP (1979) Obesity, lipids, and glucose intolerance. The Framingham Study. Am J Clin Nutr 32:1238–1245PubMed
4.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
5.
go back to reference Rathmann W, Haastert B, Icks A et al (2003) High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 46:182–189PubMed Rathmann W, Haastert B, Icks A et al (2003) High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 46:182–189PubMed
6.
go back to reference Rathmann W, Strassburger K, Heier M et al (2009) Incidence of Type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabet Med 26:1212–1219PubMedCrossRef Rathmann W, Strassburger K, Heier M et al (2009) Incidence of Type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabet Med 26:1212–1219PubMedCrossRef
7.
go back to reference Herder C, Hauner H, Haastert B et al (2006) Hypoadiponectinemia and proinflammatory state: two sides of the same coin?: results from the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4). Diab Care 29:1626–1631CrossRef Herder C, Hauner H, Haastert B et al (2006) Hypoadiponectinemia and proinflammatory state: two sides of the same coin?: results from the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4). Diab Care 29:1626–1631CrossRef
8.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486–2497 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486–2497
9.
go back to reference Hivert MF, Sullivan LM, Fox CS et al (2008) Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 93:3165–3172PubMedCrossRef Hivert MF, Sullivan LM, Fox CS et al (2008) Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 93:3165–3172PubMedCrossRef
10.
go back to reference Lindsay RS, Funahashi T, Hanson RL et al (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–58PubMedCrossRef Lindsay RS, Funahashi T, Hanson RL et al (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–58PubMedCrossRef
11.
go back to reference Duncan BB, Schmidt MI, Pankow JS et al (2004) Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 53:2473–2478PubMedCrossRef Duncan BB, Schmidt MI, Pankow JS et al (2004) Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 53:2473–2478PubMedCrossRef
12.
go back to reference Snehalatha C, Mukesh B, Simon M, ViswaNathan V, Haffner SM, Ramachandran A (2003) Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diab Care 26:3226–3229CrossRef Snehalatha C, Mukesh B, Simon M, ViswaNathan V, Haffner SM, Ramachandran A (2003) Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diab Care 26:3226–3229CrossRef
13.
go back to reference Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N (2007) Adipokines and risk of type 2 diabetes in older men. Diab Care 30:1200–1205CrossRef Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N (2007) Adipokines and risk of type 2 diabetes in older men. Diab Care 30:1200–1205CrossRef
14.
go back to reference Hotta K, Funahashi T, Bodkin NL et al (2001) Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126–1133PubMedCrossRef Hotta K, Funahashi T, Bodkin NL et al (2001) Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126–1133PubMedCrossRef
Metadata
Title
Insulin resistance influences the association of adiponectin levels with diabetes incidence in two population-based cohorts: the Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 study and the Framingham Offspring Study
Authors
M.-F. Hivert
L. M. Sullivan
P. Shrader
C. S. Fox
D. M. Nathan
R. B. D’Agostino Sr
P. W. F. Wilson
B. Kowall
C. Herder
C. Meisinger
B. Thorand
W. Rathmann
J. B. Meigs
Publication date
01-05-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2067-y

Other articles of this Issue 5/2011

Diabetologia 5/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.